DNX-2401 Demonstrates “Dramatic” Survival Benefit in Glioma
Treatment with the investigational agent DNX-2401 resulted in 20% of a cohort of patients with recurrent malignant glioma surviving more than 3 years from the time of treatment. Frederick F.…
